Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer

Ayisha Sharma

News Reporter

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients with a challenging form of ovarian cancer, sending its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Cor­cept shares soar af­ter Phase 3 win in plat­inum-re­sis­tant ovar­i­an can­cer

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer